MARKET

ACHFF

ACHFF

Arch Biopartners
OTCMQB
0.880
-0.017
-1.90%
Closed 15:51 12/26 EST
OPEN
0.880
PREV CLOSE
0.897
HIGH
0.880
LOW
0.880
VOLUME
100
TURNOVER
88
52 WEEK HIGH
1.410
52 WEEK LOW
0.650
MARKET CAP
58.90M
P/E (TTM)
-31.7690
1D
5D
1M
3M
1Y
5Y
1D
Arch granted ethics approval for St. Michaels participation in Phase II trial
TipRanks · 12/16 12:45
Arch Biopartners Wins Ethics Approval for Phase II Cardiac Surgery-Associated AKI Trial at St. Michael’s Hospital
Reuters · 12/16 12:40
Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
Barchart · 12/16 06:40
Arch Biopartners Raises $600,000 in Private Placement of Common Shares
Reuters · 11/19 21:34
ARCH BIOPARTNERS CLOSES NON-BROKERED PRIVATE PLACEMENT
Reuters · 11/19 21:27
Arch biopartners launches non-brokered private placement
Seeking Alpha · 11/10 14:16
Arch Biopartners Announces $500,000 Private Placement of Common Shares
Reuters · 11/10 13:20
ARCH BIOPARTNERS ARRANGES NON-BROKERED PRIVATE PLACEMENT
Reuters · 11/10 13:10
More
About ACHFF
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.

Webull offers Arch Biopartners Inc stock information, including OTCMQB: ACHFF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHFF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHFF stock methods without spending real money on the virtual paper trading platform.